NCT06804395 CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
| NCT ID | NCT06804395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hackensack Meridian Health |
| Condition | Cancer Risk |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2034-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-10-01 with a primary completion date of 2034-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.
Eligibility Criteria
* Adults ( 18 and older) * Ability to provide own consent * Must meet at least one of the below criteria, Indicating an increased risk for cancer, any of the following: * Family or personal history suggests a familial/hereditary disorder known or suspected of predisposition to cancer. * Personal factors associated with an increased risk for cancer include benign breast disease, polyps, tobacco use, etc.as defined by the investigator. * Family members of participating individuals. * Any participant in the HICAP program regardless of cancer risk
Contact & Investigator
Elias Obeid, MD, MPH
PRINCIPAL INVESTIGATOR
Hackensack Meridian Health
Frequently Asked Questions
Who can join the NCT06804395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06804395 currently recruiting?
Yes, NCT06804395 is actively recruiting participants. Contact the research team at Lee.ifhar@hmhn.org for enrollment information.
Where is the NCT06804395 trial being conducted?
This trial is being conducted at Totowa, United States.
Who is sponsoring the NCT06804395 clinical trial?
NCT06804395 is sponsored by Hackensack Meridian Health. The principal investigator is Elias Obeid, MD, MPH at Hackensack Meridian Health. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.